Mizuho Securities Reiterates Xeris Pharmaceuticals (XERS), Lowers PT to $6
Tweet Send to a Friend
Mizuho Securities analyst Vamil Divan reiterated a Buy rating and lowered PT to $6.00 (from $8) on Xeris Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
